On February 27, Sanofi announced that dupilumab had received formal approval from the NMPA for two new indications: first, for the treatment of adult bullous pemphigoid; and second, for maintenance treatment in children aged 6 years and older with asthma.
This dual approval means that dupilumab has become the first and currently the only targeted biologic approved in China for bullous pemphigoid, as well as the first and currently the only anti-IL-4Ralpha monoclonal antibody in China covering children with asthma aged 6 years and older, bringing breakthrough innovative treatment options to these two patient groups.
Bullous pemphigoid is a serious autoimmune disease characterized by severe itching, blisters, skin erythema, and painful lesions. It seriously affects quality of life and is often accompanied by neurologic and cardio-cerebrovascular diseases, with complications such as secondary infection potentially increasing mortality risk. Data show that the average age in Chinese studies of patients with bullous pemphigoid is 64 to 73 years, and the incidence is increasing in the elderly population.
At present, the main treatments for bullous pemphigoid remain glucocorticoids and immunosuppressants, but long-term use may lead to side effects, and patients urgently need safer and more effective innovative treatment options. The approval of this new indication makes dupilumab the first and only targeted drug in China for bullous pemphigoid.
At the 2025 Annual Meeting of the American Academy of Dermatology, positive results from the pivotal Phase II/III ADEPT trial were presented. The trial was designed to evaluate the efficacy and safety of dupilumab in adults with moderate to severe bullous pemphigoid.
The trial enrolled 106 adults with moderate to severe bullous pemphigoid, who were randomized to receive dupilumab 300 mg every two weeks after a loading dose, or placebo, each in combination with standard oral corticosteroids.
The results showed that the ADEPT trial met all primary and key secondary endpoints, defined as sustained disease remission at Week 36, meaning corticosteroid tapering completed within 16 weeks with no relapse and no rescue medication used through Week 36. Compared with placebo, the dupilumab group showed the following:
The sustained remission rate was five times higher, with 20% of patients in the dupilumab group achieving sustained remission versus only 4% in the placebo group, P=0.014.
Disease severity improved significantly, with 40% of patients achieving more than 90% reduction in disease severity compared with 10% in the placebo group, P=0.0003.
Pruritus improved rapidly, with 40% of patients achieving clinically meaningful itch improvement compared with 11% in the placebo group, P=0.0006.
Corticosteroid exposure was reduced, with mean cumulative oral corticosteroid exposure decreasing by 1,678 mg, P=0.0220, and the risk of rescue medication use decreasing by 54%, P=0.0016.
The proportion of serious adverse events was higher in the placebo group than in the dupilumab group. In the study overall, 96.2% of patients reported treatment-emergent adverse events, and the rate of serious adverse events was 30.2% in the placebo group versus 22.6% in the dupilumab group.
At present, there are still unmet treatment needs in pediatric asthma in China. For children with type 2 asthma whose disease remains inadequately controlled despite medium- or high-dose inhaled corticosteroids combined with long-acting beta2 agonists and other drugs, dupilumab provides a new option for precision targeted therapy.
On this basis, a real-world study conducted by Sanofi in Chinese children with moderate to severe asthma, especially those aged 6 to 11 years, showed that dupilumab significantly reduced the frequency of asthma exacerbations, rapidly improved lung function, effectively controlled asthma symptoms, and reduced the use of inhaled corticosteroids, thereby potentially reducing the risk of related adverse effects. The results of this real-world study also supported the approval of the pediatric indication.
Dupilumab is a fully human monoclonal antibody jointly developed by Sanofi and Regeneron Pharmaceuticals. By inhibiting the signaling pathways of interleukin-4 and interleukin-13, it precisely regulates inflammatory responses. At present, it has been approved in more than 60 countries and regions worldwide, with indications covering atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other diseases.
Since its first approval in 2017, dupilumab has continued to expand its indications and demonstrated clear clinical advantages, driving steadily rising sales. In 2025, global sales reached USD 17.774 billion, up 26.16% year over year, making it the top-selling drug in autoimmune disease.